Trial Profile
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cobimetinib (Primary) ; Ipatasertib (Primary) ; Ladiratuzumab-Vedotin (Primary) ; Selicrelumab (Primary) ; Carboplatin; Eribulin; Gemcitabine; Paclitaxel; Sacituzumab govitecan; Tocilizumab
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Morpheus-panBC
- Sponsors Genentech; Roche
- 08 Sep 2023 Status changed from active, no longer recruiting to recruiting.
- 07 Jun 2023 Number of arms changed from 8 to 12. Enrollment is closed for 4 experimental arms. Experimental arms Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib + Fulvestrant, Inavolisib (6 mg) + Trastuzumab Deruxtecan and Inavolisib (9 mg) + Trastuzumab Deruxtecan added to study protocol. Study acronym changed from Morpheus-TNBC to Morpheus-panBC.
- 07 Jun 2023 Planned End Date changed from 3 May 2024 to 3 May 2026.